The spin-off Accure Therapeutics receives $1.6 million for clinical trials of an innovative Parkinson’s drug
The spin-off from the University of Barcelona (UB), Accure Therapeutics, has received two grants totaling $1.6 million to accelerate the clinical development of its drug ACT-02, aimed at treating Parkinson’s disease.
This is an innovative asset with disease-modifying potential that inhibits prolyl-endopeptidase (PREP), a protein previously underexplored for Parkinson’s disease but showing promising potential.
The ACT-02 program is in an advanced preclinical phase and is supported by positive efficacy data from in vivo Parkinson’s models, as well as a set of toxicological and pharmacological safety data.
The grants, awarded by The Michael J. Fox Foundation and Fonds National de la Recherche, represent an important milestone for the UB spin-off, reinforcing the scientific strength of ACT-02, its associated R&D plans, and its potential to address critical unmet medical needs for Parkinson’s.